Allergy/Asthma News

Omalizumab is effective and safe for the treatment of chronic urticaria, demonstrating high discontinuation due to well-controlled disease, according to a study.

In this video, Priya J. Bansal, MD, FAAAAI, FACAAI, discusses the challenge of prior authorization and its effect on physicians as part of Healio’s Women in Allergy video corner series.

Health care providers know of the broad potential AI offers for reducing burnout, but which products are actually available for use can be difficult to ascertain, especially considering electronic health record system compatibility.

A clinical decision support tool prompted pediatric providers to ask families about introducing peanuts into their infants’ diets during well child visits, according to a study published in The Journal of Allergy & Clinical Immunology.

Communities with warehouses were exposed to an average of 17.9% more nitrogen dioxide than other communities, according to a study published in Nature Communications.

Healio has compiled July’s most-read news in asthma and allergy.

The FDA has approved Palforzia for children aged 1 to 3 years who have a peanut allergy that has been diagnosed by a physician, according to a press release from its manufacturer, Stallergenes Greer.

Patients with cold urticaria and symptomatic dermographism experienced clinically meaningful and statistically significant complete responses with barzolvolimab, according to a webinar by Celldex Therapeutics.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

The incidence and prevalence of Alzheimer’s disease was positively associated with an increased risk for asthma, according to a study published in The Journal of Allergy and Clinical Immunology.